The National Institutes of Health could face a fundamental change in how it approves federal biomedical research grants. Reuters, citing Politico, reports that President Trump has directed Budget Director Russell Vought to draft an executive order establishing a new board with final authority over NIH grant funding decisions, a move that would give the White House direct, unanimous-vote control over how the country’s largest funder of biomedical research spends its money.
What the Proposed Board Would Do
According to the Politico report, the proposed board would include NIH Director Jay Bhattacharya and Vought, director of the White House Office of Management and Budget, and would be required to reach unanimous agreement before any grant could be funded. That structure would give Vought, a budget official rather than a scientist or physician, direct veto power over individual NIH grant decisions, a level of White House involvement in agency-level research funding that goes well beyond how federal science funding has traditionally operated, where career scientific staff and peer-review panels have historically driven funding decisions with agency leadership providing oversight rather than case-by-case sign-off.
The Oval Office Clash That Preceded It
The reported push for a formal board follows a tense Oval Office meeting, described to The Washington Post by three people familiar with the discussion, in which Vought pressed Trump directly on NIH’s grant-making, accusing the agency of continuing to fund what he characterized as “woke” initiatives that conflict with the administration’s priorities, including an existing executive order barring what it calls “equity-related” grants and contracts. Bhattacharya defended how the roughly $47 billion agency awards its funding. According to the Post’s sources, Trump appeared receptive to Vought’s complaints during the meeting.
This Builds on a Year of Escalating Oversight
The proposed board wouldn’t emerge from nowhere. It follows an August 2025 executive order that already required political appointees to sign off on federal research grants, one NIH leadership has maintained does not represent a change from past practice. More recently, in May 2026, the Office of Management and Budget released a 412-page draft regulation that would give political appointees final say over federal research grants across government agencies more broadly, including a provision allowing grant “termination based on the discretion of the Federal agency,” a notably broader standard than the “for cause” termination authority agencies have traditionally relied on. That broader rule has not taken effect; a funding measure currently blocks its implementation until December.
Why the Administration Says Oversight Is Needed
Vought has been publicly consistent about his view of the agency, previously telling CBS’s “Face the Nation” that NIH “needs dramatic overhaul.” The administration’s stated rationale, laid out in the May regulatory proposal, frames tighter political oversight as necessary to prevent research agencies from what it describes as promoting “a woke policy agenda that did not reflect the values of the vast majority of the American public,” and to ensure funded research aligns with the administration’s stated priorities. NIH has already cut hundreds of millions of dollars in funding over the past year for research tied to minority, gay, and transgender communities, and has issued fewer grants addressing women’s health topics, according to Washington Post reporting on the agency’s funding patterns.
Why Scientists and Some Lawmakers Are Alarmed
Critics, including many working scientists, argue the proposal would effectively replace peer review, the traditional system in which subject-matter experts evaluate research proposals on scientific merit, with the judgment of political appointees who may lack the scientific background to assess complex research proposals. Carrie Wolinetz, a former senior NIH administrator now working as a lobbyist, described the broader push as amounting to what she called the true politicization of science. Representative Zoe Lofgren of California called an earlier version of the grantmaking executive order “nothing short of obscene,” questioning why political appointees, whom she described as unelected, should be making determinations about which science gets funded. Federal judges have also repeatedly sided with NIH- and NSF-funded researchers who challenged the administration’s earlier grant terminations in court this year, finding those actions unlawful.
Where Congress Stands
Congressional appropriators in both chambers have so far pushed back against the administration’s broader funding priorities for NIH. A House Appropriations subcommittee advanced a bill on a party-line vote that would provide $46.9 billion for NIH in fiscal year 2026, a slight increase over current funding, while the Senate Appropriations Committee separately recommended $48.7 billion, a similar figure. Both amounts reject the administration’s proposal to cut the agency’s budget by 40 percent. Polling cited in Washington Post reporting has also found bipartisan majorities opposed to cutting health research funding, and some Republican lawmakers have resisted deeper reductions to NIH’s budget as well, suggesting the political appetite for aggressive NIH funding cuts doesn’t map cleanly onto party lines.
What Comes Next
For now, the reported grant-approval board remains a directive to draft an executive order rather than a finalized policy, and it joins a broader pattern of this year’s federal health agencies undergoing significant process changes under the current administration, from new FDA pilot programs aimed at reshaping how drug trials get approved to now this proposed restructuring of how NIH itself decides which biomedical research gets funded. Whether the board moves from directive to actual executive order, and how it would coexist with a Congress that has so far resisted the administration’s steeper NIH funding cuts, remains to be seen.